INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ:INO) has announced its participation in several upcoming scientific conferences to present data on its lead candidate INO-3107 and DNA medicine technologies. At the National HPV Conference in Indianapolis on April 15, the company will present results showing a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.
The company will also participate in the World Vaccine Congress in Washington, DC (April 21-23), where they will discuss their DNA-encoded monoclonal antibody (DMAb鈩�) technology and DNA immunotherapeutics for cancer and viral diseases. Additionally, INOVIO will present at the Festival of Biologics in San Diego on April 23, focusing on INO-3107 for Recurrent Respiratory Papillomatosis. Abstracts will be available on INOVIO's website after the presentations.
INOVIO (NASDAQ:INO) ha annunciato la sua partecipazione a diverse conferenze scientifiche in arrivo per presentare dati sul suo candidato principale INO-3107 e sulle tecnologie della medicina DNA. Alla Conferenza Nazionale HPV a Indianapolis il 15 aprile, l'azienda presenter脿 risultati che mostrano un tasso di risposta complessivo del 72% nel Primo Anno per il trattamento della Papillomatosi Respiratoria Ricorrente causata da HPV-6 e 11.
L'azienda parteciper脿 anche al World Vaccine Congress a Washington, DC (21-23 aprile), dove discuter脿 della sua tecnologia di anticorpi monoclonali codificati da DNA (DMAb鈩�) e degli immunoterapici a base di DNA per il cancro e le malattie virali. Inoltre, INOVIO presenter脿 al Festival of Biologics a San Diego il 23 aprile, concentrandosi su INO-3107 per la Papillomatosi Respiratoria Ricorrente. Gli abstract saranno disponibili sul sito web di INOVIO dopo le presentazioni.
INOVIO (NASDAQ:INO) ha anunciado su participaci贸n en varias conferencias cient铆ficas pr贸ximas para presentar datos sobre su candidato principal INO-3107 y las tecnolog铆as de medicina de ADN. En la Conferencia Nacional de VPH en Indian谩polis el 15 de abril, la empresa presentar谩 resultados que muestran una tasa de respuesta general del 72% en el Primer A帽o para el tratamiento de Papilomatosis Respiratoria Recurrente causada por VPH-6 y 11.
La empresa tambi茅n participar谩 en el World Vaccine Congress en Washington, DC (21-23 de abril), donde discutir谩n su tecnolog铆a de anticuerpos monoclonales codificados por ADN (DMAb鈩�) y los inmunoterap茅uticos de ADN para el c谩ncer y enfermedades virales. Adem谩s, INOVIO presentar谩 en el Festival de Biol贸gicos en San Diego el 23 de abril, centr谩ndose en INO-3107 para la Papilomatosis Respiratoria Recurrente. Los res煤menes estar谩n disponibles en el sitio web de INOVIO despu茅s de las presentaciones.
INOVIO (NASDAQ:INO)電� 欤检殧 頉勲炒鞚� INO-3107 氚� DNA 鞚橅暀 旮办垹鞐� 雽�頃� 雿办澊韯半ゼ 氚滍憸頃橁赴 鞙勴暣 雼り皜鞓る姅 鞐煬 瓿柬暀 須岇潣鞐� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 4鞗� 15鞚� 鞚鸽敂鞎犽倶韽措Μ鞀れ棎靹� 鞐措Μ電� 甑皜 HPV 須岇潣鞐愳劀 鞚� 須岇偓電� HPV-6 氚� 11搿� 鞚疙暅 鞛皽靹� 順疙潯旮� 鞙犽憪膦呾 旃橂毳� 鞙勴暅 1雲� 彀� 鞝勳泊 氚橃潙毳犾澊 72%霛茧姅 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
鞚� 須岇偓電� 霕愴暅 4鞗� 21鞚茧秬韯� 23鞚缄箤歆� 鞗岇嫳韯� DC鞐愳劀 鞐措Μ電� World Vaccine Congress鞐� 彀胳棳頃橃棳 DNA搿� 鞚胳綌霐╇悳 雼伌搿� 頃泊(DMAb鈩�) 旮办垹 氚� 鞎旉臣 氚旍澊霟姢 歆堧硲鞚� 鞙勴暅 DNA 氅挫棴旃橂鞝滌棎 雽�頃� 雲检潣頃� 瓴冹瀰雼堧嫟. 霕愴暅 INOVIO電� 4鞗� 23鞚� 靸岆敂鞐愳澊瓿犾棎靹� 鞐措Μ電� 靸濍頃� 於曥牅鞐愳劀 鞛皽靹� 順疙潯旮� 鞙犽憪膦呾鞐� 雽�頃� INO-3107鞐� 歆戩頃橃棳 氚滍憸頃� 瓴冹瀰雼堧嫟. 氚滍憸 頉� INOVIO鞚� 鞗轨偓鞚错姼鞐愳劀 齑堧鞚� 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
INOVIO (NASDAQ:INO) a annonc茅 sa participation 脿 plusieurs conf茅rences scientifiques 脿 venir pour pr茅senter des donn茅es sur son candidat principal INO-3107 et sur les technologies de m茅decine ADN. Lors de la Conf茅rence Nationale sur le VPH 脿 Indianapolis le 15 avril, l'entreprise pr茅sentera des r茅sultats montrant un taux de r茅ponse global de 72 % au cours de la premi猫re ann茅e pour le traitement de la Papillomatose Respiratoire R茅currente caus茅e par le VPH-6 et 11.
L'entreprise participera 茅galement au World Vaccine Congress 脿 Washington, DC (21-23 avril), o霉 elle discutera de sa technologie d'anticorps monoclonaux cod茅s par ADN (DMAb鈩�) et des immunoth茅rapies 脿 base d'ADN pour le cancer et les maladies virales. De plus, INOVIO pr茅sentera au Festival of Biologics 脿 San Diego le 23 avril, en se concentrant sur INO-3107 pour la Papillomatose Respiratoire R茅currente. Les r茅sum茅s seront disponibles sur le site Web d'INOVIO apr猫s les pr茅sentations.
INOVIO (NASDAQ:INO) hat seine Teilnahme an mehreren bevorstehenden wissenschaftlichen Konferenzen angek眉ndigt, um Daten zu seinem Hauptkandidaten INO-3107 und DNA-Medizin-Technologien zu pr盲sentieren. Auf der Nationalen HPV-Konferenz in Indianapolis am 15. April wird das Unternehmen Ergebnisse pr盲sentieren, die eine Gesamtansprechrate von 72 % im ersten Jahr f眉r die Behandlung von wiederkehrender Atemwegspapillomatose, die durch HPV-6 und 11 verursacht wird, zeigen.
Das Unternehmen wird auch am World Vaccine Congress in Washington, DC (21.-23. April) teilnehmen, wo sie ihre DNA-kodierte monoklonale Antik枚rper-Technologie (DMAb鈩�) und DNA-Immuntherapeutika f眉r Krebs und Viruskrankheiten diskutieren werden. Dar眉ber hinaus wird INOVIO am 23. April beim Festival of Biologics in San Diego pr盲sentieren und sich auf INO-3107 f眉r wiederkehrende Atemwegspapillomatose konzentrieren. Abstracts werden nach den Pr盲sentationen auf der Website von INOVIO verf眉gbar sein.
- None.
- None.
National HPV Conference (
April 15:
- Oral presentation:听DNA Immunotherapy (INO-3107) Results in a
72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11 - 笔补苍别濒:听Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences 鈥� Moderated by Kim McClellan, RRP Foundation President
World Vaccine Congress (
April 21:
- Oral presentation:听A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb鈩�) as Next Gen DNA Medicine
April 23:
- Oral presentation:听DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases
Festival of Biologics (
April 23:
- Oral presentation:听Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit .
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505,听[email protected]
听
View original content to download multimedia:
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What is the success rate of INOVIO's INO-3107 treatment for RRP?
Which scientific conferences will INOVIO (INO) present at in April 2025?
What new technology will INOVIO showcase at the World Vaccine Congress 2025?
What diseases does INOVIO's DNA medicine portfolio target?
When will INOVIO's presentation abstracts be available to the public?
